ArticleBMC medicine2025
Extrahepatic disease clusters and mortality in people with steatotic liver diseases: a prospective analysis of 64,749 females and 113,587 males in the UK Biobank.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Associations between use of aspirin and magnetic resonance imaging-derived liver fat and fibroinflammation.Diabetes, obesity & metabolism · 2026Article
- Measures of comorbid cardiometabolic burden and cardiovascular disease risk in people with MRI-confirmed steatotic liver disease: a prospective cohort study.Cardiovascular diabetology · 2026Article
- New Challenges in the Study of Liver Diseases: From Molecular Pathogenesis to Therapeutic Approaches (3rd Edition).Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSteatotic liver disease (SLD) is the most prevalent chronic liver disease worldwide and linked to various liver and extrahepatic diseases. However, the clustering of extrahepatic conditions and their impact on mortality in individuals with SLD remain poorly understood.
methodsWe used UK Biobank data to identify sex-specific disease clusters among individuals with SLD and multimorbidity (having ≥ 2 extrahepatic diseases) using latent class analysis. Multivariable Cox models were used to assess associations between multimorbidity, disease clusters and all-cause mortality and mortality from cardiovascular diseases (CVD), extrahepatic cancers, liver-related diseases and hepatocellular carcinoma.
resultsAmong 178,336 (36.3% female) individuals with SLD, during a median follow-up of 13.8 years, multimorbidity increased mortality by 100% (hazard ratio (95% confidence interval): 2.00 (1.93, 2.08)) and 80% (1.80 (1.71, 1.90)) in males and females, respectively, and increased the risk of death from CVD, extrahepatic cancers and liver-related diseases. Among 36,002 (43.9% female) of the 178,336 with multimorbidity, we identified five disease clusters in both sexes: related to respiratory, mental health, cancer/osteoarthritis and cardiovascular diseases. Males had separate heart and stroke clusters, whereas females had a combined heart/stroke cluster and a unique thyroid cluster. CVD was the leading cause of death in cardiovascular clusters, whereas extrahepatic cancers were the most common cause of death in other clusters. Among all disease clusters, cardiovascular clusters exhibited the highest all-cause mortality risk: 2.90 (2.64, 3.20) for the heart/stroke cluster in females and 2.63 (2.48, 2.78) for the heart cluster and 2.36 (2.16, 2.58) for the stroke cluster in males. All clusters exhibited increased mortality of CVD and extrahepatic cancers.
conclusionsMultimorbidity doubled the death rate in people with SLD. Common multimorbidity clusters of mental health, respiratory, cancer and cardiovascular diseases were found and were associated with varying mortality, with cardiovascular-related clusters showing the highest risk. Females exhibited a unique thyroid disease cluster. These findings highlight the need for tailored prevention and management strategies in SLD populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.